INgezim® COVID 19 N/S DUAL CROM
CE-marked dual recognition lateral flow assay for the detection of antibodies specific to Nucleocapsid and Spike protein of SARS-CoV-2 in blood or, serum samples.
INgezim® COVID 19 N/S DUAL CROM is designed to qualitatively determine the total antibodies specific for SARS-CoV-2 Nucleocapsid (N) and Spike (S) protein in human serum or blood samples. It is a double assay composed of two devices, one purple (for detection of N-specific antibodies) and another one blue (for detection of S-specific antibodies). This is a rapid, point-of-care test, thus, it can be carried out outside the laboratory. In the EU, these point-of-care diagnostic tests for COVID-19 are intended for use by health professionals. The product cannot be used by individuals as it is NOT a self-diagnosis test.
As a serological test, this tool is complementary to direct detection of the pathogen and can assist in the gathering of epidemiological information on disease prevalence. Furthermore, it allows the evaluation of the immunologic response of an individual after receiving the vaccine.
|Test principle||Dual recognition lateral flow assay|
|Assay time||Less than 15 minutes|
|No. of tests||2 x 20 (N-specific antibodies devices & S-specific antibodies devices)|